ANABAnaptysBio, Inc.

$45.97+231% 1Y

$45.97

$13.9752 weeks$69.82

ANAB in its own filings

Nothing in ANAB's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

201

Events found in the filings · across 725 filings · the record starts in 2015

Hard flags: none
Hard flags
Most recent filing: Sep 21, 2026
Most recent filing · Form 10-KT
Record starts: Aug 14, 2015
Record starts · the earliest filing Ryufin holds for this name

Details›

SEC comment-letter activity23 occurrences: 2024-11-13

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 21, 2026Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update.Material event (exhibits only) · press release
Jun 22, 2026On June 15, 2026, AnaptysBio, Inc. (the “Company”), entered into a Sublease Agreement (the “Sublease”) with First Tracks Biotherapeutics, Inc., a Delaware corporation (“First Tracks”), pursuant to which the Company agreed to sublease to First Tracks approximately 45,057 rentable square feet of space located at 10770 …Material agreement entered · Form 8-K
May 21, 2026On May 18, 2026, the Board of Directors of AnaptysBio, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from December 31 to June.Charter/bylaw amendment or fiscal-year change · Form 8-K
May 12, 2026Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
May 11, 2026Appointment of Chief Financial Officer On May 11, 2026, AnaptysBio, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Christopher M. Murphy as Chief Financial Officer, effective as of May 11, 2026.Director or officer change · Form 8-K
Apr 24, 2026Spin-Off of First Tracks Biotherapeutics.Material event (exhibits only) · press release
Apr 20, 2026In connection with the Spin-Off, the Company and First Tracks Biotherapeutics entered into a separation and distribution agreement (the “Separation and Distribution Agreement”) and a transition services agreement (the “Transition Services Agreement”) to effect the Spin-Off.Material agreement entered · Form 8-K
Mar 27, 2026On March 26, 2026, First Tracks Biotherapeutics and EcoR1 Capital Fund Qualified, L.P. (the “Selling Stockholder”) entered into a purchase agreement (the “Purchase Agreement”) with certain third party investors (collectively, the “Investors”), pursuant to which SpinCo agreed to issue and sell an aggregate 5,791,478 …Material agreement entered · Form 8-K
Mar 3, 2026Anaptys Provides Update on Business Separation and.Earnings release · press release